May 10 (SeeNews) - US healthcare devices provider Sanuwave Health said it has chosen Ambiensys as the distributor of its dermaPACE(R) System in Romania.
"The expected revenue from this agreement will be north of $400,000 ($475,074) over the next three years," Sanuwave said in a press release on Wednesday.
The device's mechanism of action is based on the application of pulsed acoustic waves on acute and chronic defects of the skin and subcutaneous soft tissues, according to the company's website.
Ambiensys will contribute to commercialization strength locally and regionally of the dermaPACE(R) System. After training, the cognitive and clinical knowledge will be transferred by Ambiensys' certified trainers to hospitals throughout Romania to ensure the safe and effective use of the product.
Shipment of the first devices and training will occur in the second quarter of 2018 to Ambiensys.
"The decision to engage Ambiensys made to introduce the dermaPACE(R) system throughout the wound care market in Romania, which is the largest country in Southeastern Europe. It is paramount that we partner with global distributors that have complementary contacts and a positive impact within the local Romanian market," Sanuwave chairman of the board Kevin A. Richardson II said.
"It is well known that diabetes and related concerns need to be addressed within Romania and having access to outstanding technology such as Sanuwave's within the country is a remediable step towards a healthier tomorrow," he added.
Ambiensys is a Romanian service provider in the areas of consulting, training in European funding, project management and implementation.
Sanuwave Health is active in the development and commercialization of a high- energy, focused, shock wave technology that is used in devices for the repair and regeneration of bones, muscles, tendons and skin, and for the separation of solids and fluid in non-medical systems.
($=0.842 euro)